水飛薊 Milk Thistle × 肝臟健康

結論:證據支持但有警示

The broad consumer claim of milk thistle for general liver health, liver protection or liver detox is supported only by weak and inconsistent evidence.

C 🟠 C 薄弱證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

The broad consumer claim of milk thistle for general liver health, liver protection or liver detox is supported only by weak and inconsistent evidence. Every liver outcome catalogued by Examine is the surrogate biomarker Liver Enzymes (ALT/AST), graded B, with no high-quality trial demonstrating reversal of fibrosis or improvement in hard clinical endpoints such as mortality or decompensation. L2 PubMed shows the evidence is genuinely condition-specific: moderate-quality meta-analyses support modest enzyme reduction in NAFLD/MASLD and reduced anti-TB drug-induced liver injury, while chronic hepatitis C trials found little or no benefit and a 29-RCT systematic review found only 65.5% of studies reported enzyme reduction with undefined optimal dose and population. The L5 professional consensus is clearly cautious-to-negative: Mayo Clinic states it hasn't proved effective for liver health, Cleveland Clinic pairs every benefit claim with not enough science caveats, Harvard does not address it, and AASLD/AGA do not recommend it and frame supplements primarily as a cause of liver injury. Regulators reinforce this, with the EFSA liver-function claim on hold and FDA rejecting therapeutic liver claims via warning letters. Grade C reflects that real but small, surrogate-only and inconsistent evidence exists, while the vague general liver-support use remains unproven.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.43
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
80%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L5 臨床機構權威立場
0.34
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.431
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis
PMID: 38579127 2024 統合分析 n = 2,375
結論:Across 26 RCTs silymarin significantly reduced ALT (by ~12.39 U) and AST (by ~10.97 U), improved hepatic steatosis (OR 3.25), and lowered total cholesterol (SMD -0.85), triglycerides (SMD -0.62) and LDL-C (SMD -0.81) in NAFLD/NASH patients.
效應量:ALT -12.39 U; AST -10.97 U; hepatic steatosis OR 3.25
前往 PubMed
Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
PMID: 38505782 2024 統合分析
結論:Silymarin significantly reduced ALT (MD -17.12, 95% CI -28.81 to -4.43, p<0.004) and AST (MD -12.56, 95% CI -19.02 to -6.10, p<0.0001) and triglycerides; GGT showed no significant difference (p=0.07); LDL, total cholesterol, HOMA-IR and BMI unchanged.
效應量:ALT MD -17.12; AST MD -12.56; GGT NS
前往 PubMed
Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
PMID: 30733935 2019 統合分析 n = 1,198
結論:Across 5 RCTs (585 silymarin, 613 placebo) silymarin significantly reduced anti-TB DILI risk at week 4 (RR 0.33, 95% CI 0.15 to 0.75) with small protective effects on ALT (SMD -0.15), AST (SMD -0.14) and ALP (SMD -0.12); adverse event rates similar between groups.
效應量:DILI RR 0.33 (95% CI 0.15-0.75) at week 4
前往 PubMed
Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review
PMID: 38021897 2023 系統性回顧 n = 3,846
結論:Of 29 RCTs (3,846 participants, conditions 1992-2023), 65.5% reported reduced liver enzymes, 20.7% no significant change, and 13.8% elevated enzymes; authors concluded silymarin shows potential hepatoprotection but optimal dose and target populations remain undefined.
🟠 品質有限 效應量:65.5% of studies showed reduced enzymes; mixed overall
前往 PubMed
Silibinin: a toxicologist's herbal medicine?
PMID: 36222816 2022 系統性回顧
結論:Evidence is strongest for IV silibinin as supportive therapy in Amanita phalloides (amatoxin) poisoning, where it blocks hepatic uptake of alpha-amanitin; however no RCTs exist for this indication and data rely on animal studies, case series and retrospective reviews. For general hepatoprotection the evidence base remains weak.
🟠 品質有限 效應量:not quantified (no RCTs feasible for Amanita poisoning)
前往 PubMed

L4a US FDA
謹慎
Notice does not provide a basis for a GRAS determination 來源↗
L4b EU EFSA
反對
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
水飛薊素(silymarin)是水飛薊種子所提煉出的多種類黃酮總稱,被認為具有保肝的功效。在某些國家作為保肝的處方藥品,有些國家則作為保健食品。 來源↗
L4e WHO
中性
Fructus Silybi Mariae consists of the dried ripe fruits, freed from the pappus, of Silybum marianum (L.) Gaertn. (Asteraceae). [WHO Monographs on Selected Medicinal Plants, Volume 2, 2002] 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
謹慎
Milk thistle is generally safe, but it hasn't proved effective for improving liver health. 來源↗
L5c Cleveland Clinic
中性
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
反對

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

台灣社群對水飛薊護肝討論量中等且分歧:一派(常見於 regimen/Health/Tech_Job 板熬夜應酬族)認為它「對肝很好、副作用少」而推薦;另一派強調作息飲食才是根本、保健品只是輔助,並引『市售保肝藥多無效』新聞質疑。多數鄉民承認此成分名字冷門、認知度低,常與薑黃/朝鮮薊/蜆精混為一談。

💬社群實感

分歧偏正面(推薦者稱有感、肝指數正常;反對者認為作息飲食才是關鍵)

破解迷思 社群最常見的 5 個誤解
事實把水飛薊當成『邊熬夜喝酒邊吃就能護肝贖罪』的萬靈丹(實際作息飲食才是根本,保健品僅輔助)
事實把水飛薊、薑黃、朝鮮薊、蜆精、五味子混為一談視為同類『保肝聖品』(成分機轉與證據各異)
事實誤以為市售標『護肝/保肝』複方都含足量有效成分(多數 silymarin 劑量與純度不足,且台灣保健品不得宣稱療效)
事實誤以為天然萃取就無風險、可長期高劑量吃(菊科過敏、孕婦、與藥物交互作用仍需留意)
事實把它當可治療B肝/肝病的『藥』(台灣定位為輔助,無法取代抗病毒治療)
🩹 社群通報的副作用
  • 過敏反應(菊科植物過敏者)
  • 腸胃不適
  • 孕婦/哺乳期安全性未明應避免
  • 與處方藥潛在交互作用
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • GNC 奶薊草(Milk Thistle)
  • 大研生醫 薑黃朝鮮薊(常與水飛薊並列討論)
  • 永信 肝福膠囊(silymarin 指示用藥)
  • 卡幸B+(水飛薊+豬肝/肝精複方)
  • Costco/好市多通路保肝/奶薊產品

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

水飛薊護肝保養錠 水飛薊素與朝鮮薊萃取保護肝臟

代表來源 ↗
L10b · TFDA 法定身份 官方認定

目前得宣稱之保健功效共有13項,包括「護肝」在內

來源 ↗

  • 戒酒或減少飲酒
  • 體重管理與代謝風險控制
  • 病毒性肝炎疫苗接種與篩檢
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v26 engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-milk-thistle-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-liver-health-INT-milk-thistle-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "水飛薊能改善肝臟健康",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}